NASDAQ : CALC

CalciMedica, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 1.46 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 9.97M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California.

Details

NameCalciMedica, Inc.
SectorHealthcare
IndustryBiotechnology
Employees15
Founded2011
CeoA. Leheny
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS38942Q3011
Cusip38942Q301
Cik1534133
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Dr. A. Rachel Leheny Ph.D.Chief Executive Officer and Director
Eric W. RobertsChief Business Officer and Vice Chairman of the Board
Dr. Sudarshan Hebbar M.D.Chief Medical Officer
Michael J. Dunn B.A., M.B.A.President and Chief Operating Officer
Dr. Anjana Rao Ph.D.Co-Founder and Scientific Advisor
Dr. Patrick Hogan Ph.D.Co-Founder and Scientific Advisor
Dr. Stefan Feske M.D.Co-Founder and Scientific Advisor
Dr. Kenneth A. Stauderman Ph.D.Co-Founder and Chief Scientific Officer

Contact

Address505 Coast Boulevard South, Suite 307, La Jolla, California 92037, United States
Phone858 952 5500
Websitehttps://calcimedica.com